Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.79 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.63 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032571 | 1.00 | SLC7A5 (0.79) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| Hydrochloric Acid SCHEMBL5111831 | 0.99 | SLC7A5 (0.77) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| Hydrochloric Acid SCHEMBL5111827 | 0.99 | SLC7A5 (0.77) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL30655545 | 0.90 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL21946225 | 0.90 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL7261388 | 0.88 | SLC7A5 (1.00) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL2059077 | 0.88 | SLC7A5 (0.66) | SLC7A5FOLH1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2059075 | 0.88 | SLC7A5 (0.66) | SLC7A5FOLH1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL29221367 | 0.88 | SLC7A5 (0.77) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 | |
| SCHEMBL29221365 | 0.88 | SLC7A5 (0.77) | SLC7A5LOXL2CYP4F2CYP4A11FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | SLC7A5 1600/4885LOXL2 3737/4885CYP4F2 2985/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | SLC7A5 838/4885LOXL2 3195/4885CYP4F2 1035/4885 |
| US-20040224955-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | SLC7A5 1600/4885LOXL2 3737/4885CYP4F2 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.